We conducted a double-blind, randomized, placebo-controlled trial to explore how cholecalciferol, a form of vitamin D, influences depressive symptoms in individuals suffering from type 2 diabetes mellitus (T2DM). This clinical study lasted for 12 weeks and involved participants who were either given a daily dose of 4000 IU of cholecalciferol or a placebo.
Throughout the study, we measured various factors, including the participants’ depression levels using the Beck Depression Inventory-II, as well as important biological markers like C-peptide, serotonin, and neurotrophin-3.
Our findings showed a significant reduction in depression scores among those taking cholecalciferol compared to the placebo group. Additionally, we observed a notable increase in C-peptide levels, which may indicate some metabolic benefits, although no significant changes were found in serotonin and neurotrophin-3 levels.
Ultimately, while cholecalciferol appears to alleviate mild to moderate depressive symptoms in T2DM patients through improved C-peptide levels, its impact on serotonin and neurotrophin-3 remains unclear. This highlights vitamin D as a potentially helpful option for managing depression alongside diabetes.